By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Myriad Genetics slumped to a 52-week low earlier today, after the firm's stock was downgraded by investment bank JP Morgan.

Myriad fell to as low as $14.26 before rebounding slightly in the afternoon to $14.75 — still down 6 percent on the day.

JP Morgan downgraded Myriad's stock to "neutral" from "overweight" and cut its price target to $18 from $28.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.